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Sequencing of the p53 tumour suppressor gene in human tumours
has provided several links between a specific kind of mutation and
heavy exposure to a major risk factor. The association between
sunlight exposure and tandem p53 mutations in skin cancer, and
between tobacco smoke and transversions at specific p53 guanine
hotspot residues in smokers’ lung cancer, are two clear examples,
whereas other examples of distinctive mutation profiles tentatively
associated with specific risk factors await corroboration or
plausible biological explanations.
In 1994 the presence of a specific mutation in the p53 gene
(codon 249 G®T, arg®met) in 31% of 52 lung cancers tested
from uranium miners of the Colorado Plateau USA was reported
(Taylor et al, 1994). The tumours examined were large cell cancers
(LC) and squamous cell carcinomas (SCC) of the lung. The report
was met with enthusiasm because the hotspot mutation might thus
serve as a molecular bio-dosimeter of radon, but also with skepti-
cism because alpha-particle radiation was not expected to cause
such a discrete DNA base sequence alteration (Lo et al, 1993; Hei
et al, 1994; Venitt and Biggs, 1994). Recent data, however, on
oxidative damage induced by alpha-particle traversal exclusively
through the cytoplasm of mammalian cells (Wu et al, 1999) raise
the possibility that secondary effects of high energy particle radia-
tion contribute to accumulation of G to T point mutations in DNA.
A second study of the same Colorado Plateau mining cohort, but in
which adenocarcinomas (ADC) rather than SCC and LC lung
tumours were examined did not reveal the presence of the specific
mutation in any of the 23 tumours analysed (McDonald et al,
1995), suggesting to investigators that there is histological tissue-
type specificity for the arg®met codon 249 mutation.
Uranium miners from the Saxon ore district of former East
Germany comprise the largest cohort of radon-exposed workers in
the world (Spiethoff et al, 1997). These mines are now closed, but
records confirm that working conditions were notoriously poor,
resulting in high exposure to radon and mineral dust (Schuttmann,
1993). Tissue archives (hereafter referred to as the Stollberg
Archive) containing tens of thousands of fixed tissue autopsy
samples from employees of the Wismut mining company are being
investigated now by pathologists and epidemiologists, and first
results indicate that there is a high number of lung tumours in this
Archive in comparison with pathology archives of non-mining
areas in former East Germany. The first 50 lung tumours we
screened from the Stollberg Archive revealed no arg®met hotspot
mutations (Bartsch et al, 1995; Hollstein et al, 1997). In this initial
study, nine of the 50 tumors were SCC. The aim of the present
study, therefore, was to test a larger set of SCC from the Stollberg
Archive for the putative hotspot mutation in order to explore the
proposal (McDonald et al, 1995) that the codon 249 arg®met G to




Tumour blocks (formalin-fixed, paraffin-embedded material) of
123 lung cancer patients from the Stollberg Archive with
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obtained from the Stollberg Archive in order to screen for p53 tumour suppressor gene codon 249 arg®met hotspot mutations, a putative
molecular bio-dosimeter of alpha-particle (radon) exposure (Taylor et al (1994) Lancet 343: 86–87; McDonald et al (1995) Cancer Epidemiol
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(PCR) and HaeIII restriction enzyme digestion, two tumours were found that harboured this mutation. DNA sequencing confirmed the
presence of a G to T base substitution within the HaeIII site spanning codons 249 and 250 of the p53 gene that results in replacement of
arginine (wild-type) by methionine at residue 249. When these data are combined with those from our previous study of tumours from the
Stollberg Archive in which 50 lung tumours were examined, (including nine SCCs), we conclude that the G®T (arg®met) codon 249 mutation
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pathologists were sectioned and transferred to coated glass
histology slides. Tumour cell-containing areas of haematoxylin
and eosin-stained tissue sections were marked by the pathologists,
and the percentage of tumour cells within the marked area was
recorded for each case.
Of the 123 cases, 46 were chosen for this study that provided
30% or more primary tumour cells in a marked neoplastic area at
least 16 mm2 large. Unstained sections were dewaxed, and the
tumour area was carefully microdissected and processed for DNA
extraction as previously described (Hollstein et al, 1997). Buffer
negative controls for use in subsequent polymerase chain reaction
(PCR) experiments were prepared to monitor extraction reagents
and procedures. All work up to the PCR amplification of genomic
DNA was carried out in a special laboratory reserved for pre-PCR
protocols. PCR set-up reactions were all performed with materials
shielded behind plexiglass in a PCR Template Tamer™ (Oncor,
Gaithersburg) hood equipped with a UV light source.
Polymerase chain reaction
Reactions to amplify exon 7 of the p53 tumour suppressor gene
were performed essentially as described previously (Bartsch et al,
1995). Reactions (50 ml) contained 2–4 ml of tumour DNA sample
(an estimated 10–30 ng of DNA), and DNA was amplified with
oligonucleotide primers specific for human p53 gene intron
sequences flanking exon 7. Hot-start DNA amplification was
performed with an MJ Research Minicycler programmed at 95°C
for 2 min; 35–45 cycles of 95°C (1 min), 60°C (1 min) and 72°C
(30 s). Reaction products were visualized by electrophoresis of 
5 ml PCR solution in 3.5% agarose gels (Sigma, Inc., Wide-Range
(TM) agarose), staining for 5 min in 1 mg ml–1 ethidium bromide
solution, and photography on an UV illuminated table. Fragment
size markers (PhiX-HaeIII-digested DNA) were included in each
electrophoresis.
Analysis of PCR product for the presence of base pair
substitutions at codon 249–250
PCR products were purified over Clontech-H2O-DEPC columns
(Clontech, CA, USA) and digested with restriction enzyme
HaeIII. Digestion reactions were as recommended by the manu-
facturer (Boehringer, Mannheim). Each DNA digestion reaction
and corresponding DNA control incubation (no enzyme) were
loaded side-by-side onto 3.5% agarose gels and electrophoresed 
at 90 V for 1 h. Gels were stained with ethidium bromide and
photographed. The HaeIII enzyme cleaves the wild-type p53
sequence at codon 249, but not a sequence with either the codon
249 AGG®ATG mutation or other mutants with a base change in
the GG CC recognition site spanning codons 249–250. Uncleaved
PCR product was taken as preliminary evidence for a mutation in
codons 249–250, to be verified by repeat amplification and HaeIII
digestion of exon 7, and by direct DNA sequencing of (undi-
gested) PCR product to identify the mutation. Codon 249 AGG to
ATG mutations in tumours were then re-confirmed by preparing a
new aliquot of genomic DNA extracted from a second paraffin
tissue section from the tumour, amplification by PCR and DNA
sequencing. Cycle sequencing reactions with BigDye™ (ABI,
Applied Biosystems International, Weiterstadt, Germany) fluores-
cent dye-labelled dideoxynucleotide chain terminators were then
performed according to manufacturer’s specifications and
analysed with an ABI 310 Genetic Analyzer. Samples were
sequenced twice (5¢®3¢ and 3¢®5 direction).
RESULTS
Of the 46 SCCs selected for analysis of the p53 gene, 29 (63%)
yielded DNA of sufficient quality and amount to permit single-
step PCR amplification and analysis of product by HaeIII diges-
tion. This percentage is not surprising considering that tissues
from the Stollberg Archive were subjected to extensive (several
weeks) formalin fixation, which is known to compromise severely
the quality of DNA as template for PCR. The average number of
years that these 29 patients with lung SCC were employed by the
Wismut Mining Company was 20.2, with an average of 15.7 years
underground activity. Most of these individuals began their work
in the uranium mines between 1947 and 1951, when dry drilling
procedures were still in practice, leading to very high radon expo-
sure levels (Schuttmann, 1993, and unpublished Stollberg Archive
records).
Two tumours (27 and 29) showed an altered HaeIII enzymatic
digestion profile and an AGG to ATG mutation in codon 249
(Figure 1). Repeat extraction of genomic DNA from new tissue
sections of these tumours, and mutation analysis confirmed these
results. The electropherogram of the DNA sequencing reaction
shown in the upper panel of Figure 1A shows a hemizygous AGG
to ATG mutation at codon 249 in tumour 29 (3¢®5¢ sequencing
presents this mutation as a C to A substitution), whereas tumour 27
harboured a heterozygous AGG to ATG (arginine®methionine)
mutation at the same site (Figure 1B upper panel, 5¢®3¢
sequencing). The normal p53 sequence at this location of the gene
is displayed in the lower panels of Figure 1 for comparison. These
sequencing data corroborate the HaeIII digestion patterns shown
in Figure 2. Thus we found two tumours in the set of 29 SCCs with
the codon 249 arg®met mutation reportedly linked to radon
exposure.
DISCUSSION
With the data obtained from the work described here combined
with results of our previous study, a total of 38 SCCs of the lung
from the Stollberg Archive have now been screened, two of which
were found to harbour the codon 249 arg®met mutation proposed
to be a tumour biomarker for radon exposure. Twelve such muta-
tions among the 41 SCCs examined from patients who worked in
the uranium mines of the Colorado Plateau, USA were discovered
by Taylor and colleagues (Taylor et al, 1994; McDonald et al,
1995). A comparison of results in SCC from the two cohorts
(Colorado Plateau USA vs Stollberg Archive uranium miners)
shows a clear difference in frequency (P < 0.01, c2 statistic, 
Table 1). In p53-mutant lung tumours (all histological subtypes
combined) from patients not known to have been exposed to radon
gas occupationally, the codon 249 arg®met mutation is found
occasionally, that is, in approximately one tumour per 150 tumours
with p53 mutations (IARC Human Somatic Mutation Database,
Hainaut et al, 1998). In the Stollberg Archive we found a preva-
lence of two per 79 lung tumours (histological subtypes combined)
(Table 1), whereas 16 arg®met codon 249 mutations were found
in a total of 75 lung tumours from the Colorado Plateau (P <
0.001). It appears, therefore, that the arg®met codon 249 G to T
764 Q Yang et al
British Journal of Cancer (2000) 82(4), 763–766 © 2000 Cancer Research Campaignmutation is not a conspicuous marker of radon exposure in SCC
lung cancer patients who were former uranium miners in the
Saxon Ore district of Germany, nor in the miners with other histo-
logical subtypes of lung cancer. It has been suggested that this
mutation was exceptionally prevalent in the cohort from the
Colorado Plateau because of a second mutagenic exposure (e.g. a
mycotoxin) specific to uranium mines in that area and therefore
may not be a marker of radon exposure in Colorado Plateau
workers either (Venitt and Biggs, 1994), but working circum-
stances that prevailed decades ago are difficult to verify now. With
a larger database of p53 mutations in lung carcinoma in which
details on histological subtype and patient exposure history are
available, it would be possible to explore the still tenable hypoth-
esis that the arg®met substitution at p53 residue 249, perhaps
p53 in lung tumours of miners 765
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Figure 1 DNA sequencing electropherograms, p53 exon 7. Upper panel of A shows a hemizygous codon 249 G:C to T:A mutation in tumour 29 (sequencing
performed 3¢®5¢; mutation appears as a C to A base substitution), and upper panel of B presents the heterozygous codon 249 G:C to T:A mutation in tumour
27 (sequencing performed 5¢®3¢; mutation appears as a G to T base substitution, with both G and T signals at the mutation site). Lower panels show normal
DNA sequence of p53 at this location for comparison
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Figure 2  RFLP analysis of p53 exon 7 PCR products. Agarose gel
electrophoresis of PCR products from amplification reactions with DNA from
three tumours is shown. Abbreviations: Tu, tumour; C, control PCR sample
(no enzymatic digestion); Enz, enzymatic digestion of PCR product with
HaeIII restriction enzyme; M, Biosizer V (MBI) DNA fragment size markers. In
lane 4 PCR product from tumour 29 remains undigested (mutant), whereas
tumour 27 shows partial digestion (lane 6), suggesting the presence of a
heterzygous mutation at the enzyme recognition site
Table 1 Comparison of codon 249 arg®met hotspot mutation prevalence in
archived lung cancers from two uranium mining sites
Tumour type Mining site
Colorado Plateau USAa Saxony (Stollberg) Germanyb
Tumours with the mutation/ Tumours with the mutation/
tumours tested tumours tested
Adenocarcinoma 0/23 0/15
Small cell lung cancer 0/0 0/21
Squamous cell carcinoma 12/41 2/38*
Large cell carcinoma 4/11 0/0
Mixed or unclassified 0/0 0/5
16/75 2/79**
aData from Taylor et al (1994) and McDonald et al (1995). bData from Bartsch
et al (1995) and this report. *c2 = 7.79; P < 0.01. **c2 = 13.17; P ‹‹ 0.001.induced by oxidative damage from cigarette smoke and/or cyto-
plasmic damage from alpha-particle traversal, is preferentially
selected for in bronchial squamous epithelium.
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